1. Pharmacological Effects of Atorvastatin and Cholesterol and Blood Pressure
   P. Papitha et al, 2016, Current Research in Cardiovascular Pharmacology CrossRef
2. Postconditioning with rosuvastatin reduces myocardial ischemia-reperfusion injury by inhibiting high mobility group box 1 protein expression
   XIANJIN DU et al, 2014 CrossRef
3. Atorvastatin for lowering lipids
   Stephen P Adams et al, 2015 CrossRef
4. Surgical treatment of a ventricular aneurysm in a patient with essential thrombocythemia complicated by acute myocardial infarction: A case report
   DONG-WEN WANG et al, 2014 CrossRef
5. The Role of HMGB1 in Cardiovascular Biology: Danger Signals
   Jingjing Cai et al, 2015, Antioxidants & Redox Signaling CrossRef
6. Genomic Analysis and Differential Expression of HMG and S100A Family in Human Arthritis: Upregulated Expression of Chemokines, IL-8 and Nitric Oxide by HMGB1
   Ashok R. Amin et al, 2014, DNA and Cell Biology CrossRef
7. Association of high mobility group box 1 protein with coronary artery disease
   Necla Benlier et al, 2019, Asian Cardiovasc Thorac Ann CrossRef
8. null
   Stephen P Adams et al, 2012 CrossRef
9. Short-time pretreatment of rosuvastatin attenuates myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein expression
   Bing Wu et al, 2013, International Journal of Cardiology CrossRef
10. Formulation of solid self-nanoemulsifying drug delivery systems usingN-methyl pyrrolidone as cosolvent
    Anuj G. Agrawal et al, 2015, Drug Development and Industrial Pharmacy CrossRef
11. Impact of Serum High Mobility Group Box 1 and Soluble Receptor for Advanced Glycation End-Products on Subclinical Atherosclerosis in Patients with Granulomatosis with Polyangiitis
    Alexandre W. S. de Souza et al, 2014, PLoS ONE CrossRef
12. HMGB1 in health and disease.
    Rui Kang et al, 2014, Mol Aspects Med CrossRef
13. High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statins
    Alexandre W. S. de Souza et al, 2015, Arthritis Res Ther CrossRef
14. Plasma HMGB-1 Levels in Subjects with Obesity and Type 2 Diabetes: A Cross-Sectional Study in China
    Hang Wang et al, 2015, PLoS ONE CrossRef
15. Statin protects endothelial cell against ischemia reperfusion injury through HMGB1/TLR4 pathway
    Zhaowei Zhu et al, 2016, International Journal of Cardiology CrossRef
16. HMGB1 is a promising therapeutic target for acute liver failure
    Tetsu Yamamoto et al, 2017, Expert Review of Gastroenterology & Hepatology CrossRef
17. Betulin alleviates on myocardial inflammation in diabetes mice via regulating Siti1/NLRP3/NF-κB pathway
    Yongjin Wen et al, 2020, International Immunopharmacology CrossRef
18. Rosuvastatin reduces the pro-inflammatory effects of adriamycin on the expression of HMGB1 and RAGE in rats
    Haiyan Zhang et al, 2018, Int J Mol Med CrossRef
19. Inhibition of HMGB1 involved in the protective of salidroside on liver injury in diabetes mice
    Limin Yang et al, 2020, International Immunopharmacology CrossRef
20. Statins: Neurobiological underpinnings and mechanisms in mood disorders
    Adam J. Walker et al, 2021, Neuroscience & Biobehavioral Reviews CrossRef
21. Cardiac Alarmins as Residual Risk Markers of Atherosclerosis under Hypolipidemic Therapy
    Viorel I. Suica et al, 2022, IJMS CrossRef
22. High mobility group box 1 and Dickkopf-related protein 1 as biomarkers of glucose toxicity, atherogenicity, and lower β cell function in patients with type 2 diabetes mellitus
    Hussein Kadhem Al-Hakeim et al, 2022, Growth Factors CrossRef
23. The multifunctional protein HMGB1: 50 years of discovery
    Daolin Tang et al, 2023, Nat Rev Immunol CrossRef
24. The Role of Alarmins in the Pathogenesis of Atherosclerosis and Myocardial Infarction
    Kajetan Kiełbowski et al, 2024, CIMB CrossRef